U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07700992) titled 'A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring' on July 08.
Brief Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome...